First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...

Microglial activity appears to determine when amyloid becomes biologically significant, reshaping how clinicians interpret ...

Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025. Eisai Presents New Data on the Continued ...

Mean amyloid levels remained below 24.1 centiloids at 3 years for participants who completed donanemab treatment by 1 year.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...

Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized ...

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...